Discoveries in Down syndrome: moving basic science to clinical care.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Progress in Brain Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Psychology

• Identifiers
  DOI 10.1016/B978-0-444-54299-1.00010-8PMID 22541294
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome.

  2012cited by this paper
• Genetic analysis of Down syndrome facilitated by mouse chromosome engineering

  2012cited by this paper
• The Many Substrates of Presenilin/γ-Secretase

  2011cited by this paper
• Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer’s disease

  2011cited by this paper
• The use of mouse models to understand and improve cognitive deficits in Down syndrome

  2011cited by this paper
• Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.

  2011cited by this paper
• Donepezil Significantly Improves Abilities in Daily Lives of Female down Syndrome Patients with Severe Cognitive Impairment: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial

  2011cited by this paper
• Loss of Cleavage at β′-Site Contributes to Apparent Increase in β-Amyloid Peptide (Aβ) Secretion by β-Secretase (BACE1)-Glycosylphosphatidylinositol (GPI) Processing of Amyloid Precursor Protein*

  2011cited by this paper
• APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome.

  2011cited by this paper
• On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome

  2011cited by this paper
• A new chapter in the field of memory: adult hippocampal neurogenesis

  2011cited by this paper
• Mouse Models for Down Syndrome-Associated Developmental Cognitive Disabilities

  2011cited by this paper
• Deficiency of Adult Neurogenesis in the Ts65Dn Mouse Model of Down Syndrome

  2011cited by this paper
• Behavioral Characterization of a Mouse Model Overexpressing DSCR1/ RCAN1

  2011cited by this paper
• Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.

  2011cited by this paper
• Three‐dimensional synaptic ultrastructure in the dentate gyrus and hippocampal area CA3 in the Ts65Dn mouse model of down syndrome

  2011cited by this paper
• Paper 2: EUROCAT public health indicators for congenital anomalies in Europe.

  2011cited by this paper
• Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down’s syndrome

  2010cited by this paper
• The Distributed Partnering Model for Drug Discovery and Development

  2010cited by this paper
• Development and validation of the Arizona Cognitive Test Battery for Down syndrome

  2010cited by this paper
• Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome

  2010cited by this paper
• GABAB-GIRK2-mediated signaling in Down syndrome.

  2010cited by this paper
• Reduction of Brain β-Amyloid (Aβ) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments (APP-CTFs) and Aβ Clearance*

  2010cited by this paper
• ?-Secretase as a Therapeutic Target in Alzheimer's Disease

  2010cited by this paper
• Molecular basis of pharmacotherapies for cognition in Down syndrome.

  2010cited by this paper
• Effects of voluntary physical exercise on adult hippocampal neurogenesis and behavior of Ts65Dn mice, a model of Down syndrome.

  2010cited by this paper
• Trafficking of amyloid β-precursor protein products C83 and C99 on the endocytic pathway.

  2010cited by this paper
• Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome

  2010cited by this paper
• Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice.

  2010cited by this paper
• Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006.

  2010cited by this paper
• Vesicle transport: a new player in APP trafficking.

  2010cited by this paper
• Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome

  2010cited by this paper
• A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions.

  2010cited by this paper
• Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease.

  2010cited by this paper
• BACE: Therapeutic target and potential biomarker for Alzheimer's disease.

  2010cited by this paper
• Down Syndrome: From Understanding the Neurobiology to Therapy

  2010cited by this paper
• gamma-Secretase as a therapeutic target in Alzheimer's disease.

  2010cited by this paper
• Memantine Normalizes Several Phenotypic Features in the Ts65Dn Mouse Model of Down Syndrome

  2010cited by this paper
• Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine

  2010influential reference
• Neuronal protein trafficking associated with Alzheimer disease

  2009cited by this paper
• Excitatory‐inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of down syndrome

  2009cited by this paper
• The coming of age of axonal neurotrophin signaling endosomes.

  2009cited by this paper
• Infantile Spasms and Down Syndrome: A New Animal Model

  2009cited by this paper
• Drug discovery: new models for industry-academic partnerships.

  2009cited by this paper
• Restoration of Norepinephrine-Modulated Contextual Memory in a Mouse Model of Down Syndrome

  2009influential reference
• The “Down Syndrome Critical Region” Is Sufficient in the Mouse Model to Confer Behavioral, Neurophysiological, and Synaptic Phenotypes Characteristic of Down Syndrome

  2009cited by this paper
• Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome.

  2008cited by this paper
• Sleep and EEG features in genetic models of Down syndrome.

  2008cited by this paper
• Gamma-secretase inhibition and modulation for Alzheimer's disease.

  2008cited by this paper
• Acute Injections of the NMDA Receptor Antagonist Memantine Rescue Performance Deficits of the Ts65Dn Mouse Model of Down Syndrome on a Fear Conditioning Test

  2008cited by this paper
• From presenilinase to gamma-secretase, cleave to capacitate.

  2008cited by this paper
• Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome

  2007influential reference
• Defects in Embryonic Neurogenesis and Initial Synapse Formation in the Forebrain of the Ts65Dn Mouse Model of Down Syndrome

  2007cited by this paper
• Rab5 Mediates an Amyloid Precursor Protein Signaling Pathway That Leads to Apoptosis

  2007cited by this paper
• Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: A clinical report series

  2007cited by this paper
• Synaptic and cognitive abnormalities in mouse models of down syndrome: Exploring genotype‐phenotype relationships

  2007cited by this paper
• Using mouse models to explore genotype-phenotype relationship in Down syndrome.

  2007cited by this paper
• A Functional Dynein–Microtubule Network Is Required for NGF Signaling Through the Rap1/MAPK Pathway

  2007cited by this paper
• Ts65Dn, a mouse model of Down syndrome, exhibits increased GABAB-induced potassium current.

  2007cited by this paper
• Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with down syndrome and in Ts65Dn mice

  2007cited by this paper
• Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration.

  2006influential reference
• DAPT-Induced Intracellular Accumulations of Longer Amyloid β-Proteins: Further Implications for the Mechanism of Intramembrane Cleavage by γ-Secretase†

  2006cited by this paper
• The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease

  2006cited by this paper
• Abnormal expression of the G‐protein‐activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex, and substantia nigra of Ts65Dn mouse: A model of Down syndrome

  2006cited by this paper
• DAPT-induced intracellular accumulations of longer amyloid beta-proteins: further implications for the mechanism of intramembrane cleavage by gamma-secretase.

  2006cited by this paper
• DYRK1A (Dual-Specificity Tyrosine-Phosphorylated and -Regulated Kinase 1A): A Gene with Dosage Effect During Development and Neurogenesis

  2006cited by this paper
• Improved national prevalence estimates for 18 selected major birth defects--United States, 1999-2001.

  2006cited by this paper
• Hippocampal hypocellularity in the Ts65Dn mouse originates early in development.

  2006cited by this paper
• Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome.

  2006cited by this paper
• Presenilin/γ‐secretase activity regulates protein clearance from the endocytic recycling compartment

  2006cited by this paper
• Presenilin/γ-Secretase-mediated Cleavage of the Voltage-gated Sodium Channel β2-Subunit Regulates Cell Adhesion and Migration*

  2005cited by this paper
• Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases.

  2005cited by this paper
• Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management.

  2005cited by this paper
• The consequences of chromosome imbalance.

  2005cited by this paper
• Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.

  2005cited by this paper
• Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration.

  2005cited by this paper
• Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome.

  2005cited by this paper
• Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897

  2005cited by this paper
• Hippocampal Long-Term Potentiation Suppressed by Increased Inhibition in the Ts65Dn Mouse, a Genetic Model of Down Syndrome

  2004cited by this paper
• Donepezil effects on language in children with Down syndrome: Results of the first 22‐week pilot clinical trial

  2004cited by this paper
• Synaptic structural abnormalities in the Ts65Dn mouse model of down syndrome

  2004cited by this paper
• Inhibition of G Protein-Activated Inwardly Rectifying K+ Channels by Various Antidepressant Drugs

  2004cited by this paper
• Paternal age and Down's syndrome genotypes diagnosed prenatally: No association in New York State data

  2004cited by this paper
• Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes.

  2004cited by this paper
• Aβ localization in abnormal endosomes: association with earliest Aβ elevations in AD and Down syndrome

  2004cited by this paper
• A distinct role for norepinephrine in memory retrieval.

  2004cited by this paper
• Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome.

  2004cited by this paper
• Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities.

  2004cited by this paper
• Cyclooxygenase (COX)-2 and COX-1 Potentiate β-Amyloid Peptide Generation through Mechanisms That Involve γ-Secretase Activity*

  2003cited by this paper
• App Gene Dosage Modulates Endosomal Abnormalities of Alzheimer's Disease in a Segmental Trisomy 16 Mouse Model of Down Syndrome

  2003cited by this paper
• Understanding mental retardation in Down's syndrome using trisomy 16 mouse models

  2003cited by this paper
• Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study

  2003cited by this paper
• Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration.

  2003cited by this paper
• The neuropsychology of Down syndrome: evidence for hippocampal dysfunction.

  2003influential reference
• Presenilin-1, Nicastrin, Amyloid Precursor Protein, and γ-Secretase Activity Are Co-localized in the Lysosomal Membrane*

  2003cited by this paper
• Donepezil for the treatment of language deficits in adults with Down syndrome: A preliminary 24‐week open trial

  2003cited by this paper
• Spatial representation and attention in toddlers with Williams syndrome and Down syndrome.

  2003cited by this paper
• Central challenges facing the national clinical research enterprise.

  2003cited by this paper
• Presenilin endoproteolysis mediated by an aspartyl protease activity pharmacologically distinct from γ‐secretase

  2003cited by this paper
• Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions.

  2003cited by this paper

• Chronic suppression of monoacylglycerol lipase restores adult neurogenesis in the septal but not the temporal DG in Ts65Dn mouse model of Down syndrome.

  2026cites this paper
• Early postnatal GABAB antagonist treatment normalizes inhibitory/excitatory balance in neonatal Ts65Dn mice, a genetic model of down syndrome.

  2025cites this paper
• Association of Physical Activity and Bone Mineral Density in Adults with Depressive Symptoms

  2024cites this paper
• Enhanced GIRK2 channel signaling in Down syndrome: A feasible role in the development of abnormal nascent neural circuits

  2022cites this paper
• GIRK2 Channels in Down syndrome and Alzheimer's disease.

  2022cites this paper
• Association of bone mineral density and depression in different bone sites and ages: A meta‐analysis

  2021cites this paper
• Genetics and genomics of Down syndrome

  2019cites this paper
• Down syndrome.

  2019cites this paper
• Pharmacotherapy of Down's syndrome: When and Which?

  2019cites this paper
• Developmental excitatory-to-inhibitory GABA polarity switch is delayed in Ts65Dn mice, a genetic model of Down syndrome.

  2018cites this paper
• Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.

  2017cites this paper
• The medial temporal memory system in Down syndrome: Translating animal models of hippocampal compromise

  2017cites this paper
• Epigenetic dysregulation in the developing Down syndrome cortex

  2016cites this paper
• The legacy of the benzodiazepine receptor: from flumazenil to enhancing cognition in Down syndrome and social interaction in autism.

  2015cites this paper
• Down Syndrome Cognitive Phenotypes Modeled in Mice Trisomic for All HSA 21 Homologues

  2015cites this paper
• Down syndrome: Cognitive and behavioral functioning across the lifespan

  2015influential citation
• Down syndrome and Alzheimer's disease: Common pathways, common goals

  2015cites this paper
• The non-glycosylated isoform of MIC26 is a constituent of the mammalian MICOS complex and promotes formation of crista junctions.

  2015cites this paper
• 9. Translational Tools toward Better Drug Therapy in Human Populations

  2015cites this paper
• Pathology of the Developing Mouse from Conception to Weaning

  2015cites this paper
• Monoacylglycerol Lipase Inhibitor JZL184 Improves Behavior and Neural Properties in Ts65Dn Mice, a Model of Down Syndrome

  2014cites this paper
• β1-adrenergic receptor activation enhances memory in Alzheimer's disease model

  2014cites this paper
• GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism.

  2014cites this paper
• Weaker control of the electrical properties of cerebellar granule cells by tonically active GABAA receptors in the Ts65Dn mouse model of Down’s syndrome

  2013cites this paper
• Síndrome de Down, cerebro y desarrollo Down syndrome, brain and development

  2013cites this paper
• Down syndrome, brain and development

  2013cites this paper
• Genetic and Epigenetic Mechanisms in Down Syndrome Brain

  2013cites this paper
• Attention-Deficit/Hyperactivity Disorder in Older Adults: Prevalence and Possible Connections to Mild Cognitive Impairment

  2012cites this paper
• Deficits in Cognition and Synaptic Plasticity in a Mouse Model of Down Syndrome Ameliorated by GABAB Receptor Antagonists

  2012influential citation